Company news
Scancell Holdings Plc (LSE:SCLP) news
Scancell Holdings Plc news releases on 6ix. Latest, Oct 2, 2026: Notice of GM
Press releases & updates
Notice of GM
October 2, 2026
Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development
September 24, 2026
Scancell to Present at the H.C. Wainwright Sept 26
September 3, 2026
iSCIB1+ MHRA CTA Approval for Ph3 trial
August 19, 2026
Extension of Option Exercise Period
July 31, 2026
Correction: Merger and Financing
July 24, 2026
Merger and Financing
July 23, 2026
Scancell: Response to Press Speculation
June 26, 2026
Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study
April 28, 2026
Scancell announces CFO transition
April 2, 2026
Interim Results for the six months ended 31 October 2025
January 29, 2026
Half-year Financial Report
January 29, 2026
Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma
January 26, 2026
FDA clearance of IND application for iSCIB1+
January 26, 2026
Notice of Results
January 22, 2026
Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma
December 9, 2025
Continued improvement in PFS with iSCIB1+
December 9, 2025
Research Update
November 7, 2025
Result of AGM
October 30, 2025
Notice of AGM
October 3, 2025
Director Dealing
September 16, 2025
Final Results
September 11, 2025
Director/PDMR Shareholding
August 4, 2025
Strong Phase 2 data on iSCIB1+ in Melanoma
July 22, 2025
Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+
July 22, 2025
Share Option Exercise
July 16, 2025
Scancell initiates new arm in SCOPE Phase 2 study
June 25, 2025
Investor Update via Investor Meet Company.
April 22, 2025
Partnership with NHS Cancer Vaccine Launch Pad
April 14, 2025
Scancell to present at 2025 AACR Annual Meeting
April 1, 2025
Issue of share options
February 20, 2025
Scancell presenting at AACR IO conference
February 17, 2025
Interim Results
January 30, 2025
Notice of Interim Results
January 23, 2025
Modi-1 Vaccine Achieves Early Clinical Validation
January 9, 2025
Result of Retail Offer and Total Voting Rights
December 9, 2024
Result of Placing and Subscription
December 5, 2024
Retail Offer for up to £1 million
December 4, 2024
Proposed fundraise in excess of £8.5 million
December 4, 2024
Second Commercial License Agreement with Genmab
December 4, 2024
Positive data from Phase 2 SCOPE trial with SCIB1
November 18, 2024
Result of Annual General Meeting
October 25, 2024
Holding(s) in Company
October 24, 2024
Scancell Appoints Dr Phil L’Huillier as CEO
October 22, 2024
Results Year Ended 30 April 2024
September 24, 2024
Notice of Final Results
September 18, 2024
Strategic Partnership with PharmaJet
September 17, 2024
Scancell to attend upcoming conferences
September 2, 2024
Scancell Appoints Dr Nermeen Varawalla as CMO
July 30, 2024
Update from iSCIB1+ Clinical Advisory Meeting
July 24, 2024